JP2023509186A5 - - Google Patents

Info

Publication number
JP2023509186A5
JP2023509186A5 JP2022541984A JP2022541984A JP2023509186A5 JP 2023509186 A5 JP2023509186 A5 JP 2023509186A5 JP 2022541984 A JP2022541984 A JP 2022541984A JP 2022541984 A JP2022541984 A JP 2022541984A JP 2023509186 A5 JP2023509186 A5 JP 2023509186A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
alkoxy
alkyl
formula
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022541984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7763761B2 (ja
JP2023509186A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000006 external-priority patent/WO2021140418A1/en
Publication of JP2023509186A publication Critical patent/JP2023509186A/ja
Publication of JP2023509186A5 publication Critical patent/JP2023509186A5/ja
Application granted granted Critical
Publication of JP7763761B2 publication Critical patent/JP7763761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022541984A 2020-01-08 2021-01-07 Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法 Active JP7763761B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958474P 2020-01-08 2020-01-08
US62/958,474 2020-01-08
PCT/IB2021/000006 WO2021140418A1 (en) 2020-01-08 2021-01-07 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Publications (3)

Publication Number Publication Date
JP2023509186A JP2023509186A (ja) 2023-03-07
JP2023509186A5 true JP2023509186A5 (https=) 2024-01-16
JP7763761B2 JP7763761B2 (ja) 2025-11-04

Family

ID=76788523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541984A Active JP7763761B2 (ja) 2020-01-08 2021-01-07 Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法

Country Status (9)

Country Link
US (1) US20230241064A1 (https=)
EP (1) EP4087575A4 (https=)
JP (1) JP7763761B2 (https=)
KR (1) KR20220124736A (https=)
CN (1) CN115003306A (https=)
CA (1) CA3164933A1 (https=)
IL (1) IL294344B1 (https=)
TW (1) TWI882058B (https=)
WO (1) WO2021140418A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
MX2011009852A (es) * 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HK1219434A1 (zh) * 2013-08-21 2017-04-07 Resverlogix Corp. 用於加速斑块消退的组合物和治疗方法
AU2014310371A1 (en) * 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CN109824608B (zh) * 2019-03-15 2022-06-21 深圳晶泰科技有限公司 一种Apabetalone晶型及其制备方法

Similar Documents

Publication Publication Date Title
JP5780430B2 (ja) 勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤
JP2006523216A5 (https=)
JP2008515905A5 (https=)
NZ593754A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients
ES2532210T3 (es) Métodos para el tratamiento concomitante de teofilina y febuxostat
RU2008133654A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
JP2006518731A5 (https=)
EP4596044A2 (en) Combination therapy of gpr119 agonists and dpp-4 inhibitors
JP2022541503A (ja) Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置
JP2022552881A5 (https=)
EP3820470B1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
JP2023500685A5 (https=)
US10358447B2 (en) Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
JP2023509186A5 (https=)
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
IL292696A (en) Methods for the treatment and/or prevention of severe harmful cardiovascular events with a combination of a bromodomain bet inhibitor and a sodium-dependent glucose transporter 2 inhibitor
US12226411B2 (en) Soluble guanylate cyclase activators for treating portal hypertension
US20230019280A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
JP2023547475A5 (https=)
JP2023549703A5 (https=)
JP2009532494A5 (https=)
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬